Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
21 janv. 2025 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation...
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
13 janv. 2025 07h30 HE
|
Cytokinetics, Incorporated
PDUFA Target Action Date for Aficamten Set for September 26, 2025;Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to Becoming...
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
03 janv. 2025 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate...
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
23 déc. 2024 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 déc. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 29, 2024 it granted stock options to purchase an aggregate...
Cytokinetics to Participate in December Investor Conferences
02 déc. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following December...
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
19 nov. 2024 02h30 HE
|
Cytokinetics, Incorporated
Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone Payments, withTiered Royalties on Future Sales SOUTH SAN FRANCISCO,...
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
16 nov. 2024 09h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering...
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
16 nov. 2024 09h00 HE
|
Cytokinetics, Incorporated
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data from FOREST-HCM Demonstrate Aficamten Durably Reduces...